IOVA
IOVANCE BIOTHERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$10.64
+4.42%Price chart
Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14Sep 17Sep 22
Key dataSep 22, 2026
Open$10.08
From 52W high+0.00%
Volume15.67M
Market cap$4.82B
P/E (TTM)—
P/S (TTM)14.8x
Div yield—
Key dataSep 22, 2026
Open
$10.08
From 52W high
+0.00%
Volume
15.67M
Market cap
$4.82B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−17.4x
P/E (TTM)
—
RSI (14)
74.9
MomentumView details →
1D Return
+4.42%
YTD Return
+276.19%
SummaryUpdated Jun 1, 2026
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a clinical-stage biotechnology company founded in 2007 and headquartered in San Carlos, California. Originally incorporated as Lion Biotechnologies, the company changed its name to Iovance Biotherapeutics in June 2017. The company achieved a significant milestone in February 2024 when the FDA approved its lead product <b>Amtagvi</b> (lifileucel), making it the first tumor-infiltrating lymphocyte (TIL) therapy approved for treating solid tumors. This approval transformed Iovance from a purely clinical-stage company into a commercial biotechnology enterprise focused on cancer immunotherapy.
Similar companies
Latest newsMore news →
Iovance Biotherapeutics approved inducement stock option grants covering 179,750 shares of common stock to eighteen new non-executive employees on September 17, 2026.4d agoShares of Nutex Health, AtriCure, Iovance Biotherapeutics, Centene and Concentra Group Holdings all reached 52-week highs on Monday, September 14, 2026.8d agoIovance Biotherapeutics granted inducement stock options covering 240,135 shares of common stock to twenty new non-executive employees on August 20, 2026.32d ago